Saladax Biomedical Signs Deal with Bristol-Myers Squibb to Develop Clinical Diagnostics
Publication date: 21 June 2010
Author: MacDougall Biomedical Communications
Tagged with: Bristol-Myers Squibb, Saladax Biomedical Inc, Salvatore Salamone
Saladax Biomedical, Inc. announced today that it has entered into a multi-year development and commercialization agreement with Bristol-Myers Squibb Company (NYSE: BMY ) for the development of certain clinical diagnostic tests to be used in conjunction with the development of certain therapeutic compounds in the Bristol-Myers Squibb pipeline.
“This collaboration demonstrates our capability to develop clinical diagnostics with a leading global pharmaceutical company such as Bristol-Myers Squibb,” said Dr. Salvatore Salamone, CEO of Saladax. “The breadth and flexibility of Saladax’s core scientific capabilities can be applied broadly to clinical diagnostics in different therapeutic categories.”
Under the terms of the agreement, the companies will collaborate globally on development and regulatory approvals. Saladax received exclusive global rights to commercialize the assays it develops. Financial terms are not disclosed.
Advertisement:
Email newsletter
If you enjoyed this article sign-up to receive our bi-weekly email newsletter:
Latest news
- Daiichi Sankyo and the National Cancer Center form comprehensive research alliance (22 May 2012)
- Fast plasma sample cleanup with new Phree Phospholipid Removal Plates (21 May 2012)
- FDA approves new labeling for ISENTRESS® (raltegravir) (21 May 2012)
- Capital increase in Lundbeck as a result of employee warrant programme (21 May 2012)
- Two overall winners announced at prestigious national award ceremony in London’s Science Museum (18 May 2012)
In-depth focus:
Mass Spectrometry
This free to view Mass Spectrometry in-depth focus is sponsored by Waters, Bruker, Protea and Dr. Hochmuth and contains the following articles:
- Mass spectrometry in drug discovery - Proteomics, small molecules and metablomics
- Quantification of membrane drug transporters and application in drug discovery and development
- Anthony Bristow, AstraZeneca, poses the questions for our Mass Spectrometry Leaders Roundtable
Company directory
ABB Analytical Measurements | Almac | B&W Tek, Inc. | BASF | BD Diagnostics | Bio-Optronics, Inc. | bioMérieux | BioTek Instruments, Inc. | Bruker Optics | CAMO Software AS | Catalent Pharma Solutions | Chemspec Europe Ltd | CI Precision | Cisbio Bioassays | EMD Millipore | GE Analytical Instruments | Gerresheimer Group | HACH LANGE GMBH | HORIBA Scientific | I Holland Limited | Lonza | Merck Millipore | Pall Life Sciences | Patheon Inc | Phenomenex | Porvair Sciences Ltd | Randox Pharma Services | Rapid Micro Biosystems | Realia | Roche | rommelag® | Umetrics |
Login to access exclusive content